These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2125256)

  • 1. Significance of FCM-DNA measurement in detecting minimal residual disease in leukemia.
    Zhang RX; Yao EG
    Chin Med J (Engl); 1990 Oct; 103(10):826-30. PubMed ID: 2125256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of blast cell DNA content for prognosis of childhood acute lymphoblastic leukemia.
    Starý J; Hrodek O; Hausner P; Petráková A; Goetz P; Kreuger A
    Neoplasma; 1990; 37(3):293-9. PubMed ID: 2370916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of minimal residual disease in acute leukemias by flow cytometry].
    Scolnik MP
    Medicina (B Aires); 2000; 60 Suppl 2():83-6. PubMed ID: 11188938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of DNA aneuploidy as a tumor marker].
    Takamoto S
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2329-37. PubMed ID: 2751314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance and prognostic detection of minimal residual disease in acute leukemias].
    Deptała A; Widzyńska I; Kuratowska Z
    Acta Haematol Pol; 1995; 26(4):413-20. PubMed ID: 8571743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
    Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Flow cytometry in the determination of DNA aneuploidy in patients with acute leukemias].
    Shmarov DA; Kuchma IuM; Miterev GIu; Kozinets GI
    Ter Arkh; 1996; 68(7):11-4. PubMed ID: 8928064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
    Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aneuploidy as a marker of minimal residual disease in leukemia.
    Walle AJ; Niedermayer W
    Cancer Detect Prev; 1985; 8(1-2):303-15. PubMed ID: 4064049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
    Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
    Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of early marrow response in childhood aneuploid acute lymphoblastic leukemia: flow cytometric DNA analysis versus standard morphology.
    Finn LS; Hawkins DS; Rutledge JC; Patterson K
    Pediatr Dev Pathol; 2004; 7(1):39-47. PubMed ID: 15255034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A prognostic factor in childhood acute lymphoblastic leukemia: implication of cellular DNA contents. Children's Cancer and Leukemia Study Group].
    Katano N; Tsurusawa M; Kawai S; Fujimoto T
    Rinsho Ketsueki; 1989 Jul; 30(7):943-50. PubMed ID: 2810797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
    Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
    Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
    Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
    Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of the detection of minimal residual disease in the management of acute leukemia].
    Mód A; Tamáska J; Adám E; Gidáll J; Poros A; Király A; Natonek K; Pálóczi K; Hollán Z
    Orv Hetil; 1991 Jun; 132(24):1291-6, 1299. PubMed ID: 1857605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.